It depends on the standard you follow. As of September 2026, Natera, Inc. (NTRA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.15% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.16% / 30% · Interest income / Revenue 1.21% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.15% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.09% / 33% · Receivables / Mkt Cap (36m) 0.90% / 49% · Interest income / Revenue 1.21% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.15% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.09% / 33.33% · Receivables / Mkt Cap (24m) 0.90% / 33.33% · Interest income / Revenue 1.21% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 3.08% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 41.8% / 33.33% · Receivables / Avg Assets (4Q) 15.4% / 33.33% · Interest income / Revenue 1.21% / 5% | Fail |
| FTSE | Debt / Total Assets 2.92% / 33.33% · (Cash+ST Inv) / Total Assets 39.9% / 33.33% · (Cash+Recv) / Total Assets 57.1% / 33.33% · Interest income / Revenue 1.21% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Natera, Inc. (NTRA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Natera, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.21% of each dividend: Natera, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Natera, Inc. (NASDAQ: NTRA) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $41.7B. The Maz Rating grades it against the other companies in its sector.
Natera, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $287.43, Natera, Inc. trades at 14.4x sales and 22.2x book value. Over the last twelve months it generated about $2.9B of revenue and a net loss of $165M. It runs a gross margin of 65.2%, an operating margin of -9.0% and a net margin of -5.7%. It shows return on equity of -9.2%, return on invested capital of -8.5% and a free cash flow yield of 0.1%. On the balance sheet: a debt-to-equity ratio of 0.13 and a current ratio of 2.81. Over the past 52 weeks the share price ranged from $181.00 to $437.41, with a beta of 1.51.
Natera, Inc. does not currently pay a dividend.
28 Wall Street analyst ratings cover the stock: 25 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.